339 related articles for article (PubMed ID: 30190303)
1. Follow-up of Lesions with Equivocal Radiotracer Uptake on PSMA-Targeted PET in Patients with Prostate Cancer: Predictive Values of the PSMA-RADS-3A and PSMA-RADS-3B Categories.
Yin Y; Werner RA; Higuchi T; Lapa C; Pienta KJ; Pomper MG; Gorin MA; Rowe SP
J Nucl Med; 2019 Apr; 60(4):511-516. PubMed ID: 30190303
[TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
3. Prospective Comparison of PET Imaging with PSMA-Targeted
Rowe SP; Li X; Trock BJ; Werner RA; Frey S; DiGianvittorio M; Bleiler JK; Reyes DK; Abdallah R; Pienta KJ; Gorin MA; Pomper MG
J Nucl Med; 2020 Feb; 61(2):183-188. PubMed ID: 31451492
[TBL] [Abstract][Full Text] [Related]
4. Effect of Point-Spread Function Reconstruction for Indeterminate PSMA-RADS-3A Lesions on PSMA-Targeted PET Imaging of Men with Prostate Cancer.
Khatri W; Chung HW; Werner RA; Leal JP; Pienta KJ; Lodge MA; Gorin MA; Pomper MG; Rowe SP
Diagnostics (Basel); 2021 Apr; 11(4):. PubMed ID: 33917238
[TBL] [Abstract][Full Text] [Related]
5. Association of True Positivity with Serum Prostate-Specific Antigen Levels and Other Clinical Factors in Indeterminate PSMA-RADS-3A Lesions Identified on
Garg T; Werner RA; Chung HW; Khatri W; Pienta KJ; Pomper MG; Gorin MA; Saad E; Rowe SP
Tomography; 2022 Oct; 8(6):2639-2647. PubMed ID: 36412679
[TBL] [Abstract][Full Text] [Related]
6. Patterns of uptake of prostate-specific membrane antigen (PSMA)-targeted
Werner RA; Sheikhbahaei S; Jones KM; Javadi MS; Solnes LB; Ross AE; Allaf ME; Pienta KJ; Lapa C; Buck AK; Higuchi T; Pomper MG; Gorin MA; Rowe SP
Ann Nucl Med; 2017 Nov; 31(9):696-702. PubMed ID: 28831739
[TBL] [Abstract][Full Text] [Related]
7. Interobserver Agreement for the Standardized Reporting System PSMA-RADS 1.0 on
Werner RA; Bundschuh RA; Bundschuh L; Javadi MS; Leal JP; Higuchi T; Pienta KJ; Buck AK; Pomper MG; Gorin MA; Lapa C; Rowe SP
J Nucl Med; 2018 Dec; 59(12):1857-1864. PubMed ID: 30190304
[TBL] [Abstract][Full Text] [Related]
8. Changing Threshold-Based Segmentation Has No Relevant Impact on Semi-Quantification in the Context of Structured Reporting for PSMA-PET/CT.
Mihatsch PW; Beissert M; Pomper MG; Bley TA; Seitz AK; Kübler H; Buck AK; Rowe SP; Serfling SE; Hartrampf PE; Werner RA
Cancers (Basel); 2022 Jan; 14(2):. PubMed ID: 35053434
[TBL] [Abstract][Full Text] [Related]
9. The Effects of Monosodium Glutamate on PSMA Radiotracer Uptake in Men with Recurrent Prostate Cancer: A Prospective, Randomized, Double-Blind, Placebo-Controlled Intraindividual Imaging Study.
Harsini S; Saprunoff H; Alden T; Mohammadi B; Wilson D; Bénard F
J Nucl Med; 2021 Jan; 62(1):81-87. PubMed ID: 32385167
[TBL] [Abstract][Full Text] [Related]
10. Oligometastases in prostate cancer : Metabolic response in follow-up PSMA-PET-CTs after hypofractionated IGRT.
Baumann R; Koncz M; Luetzen U; Krause F; Dunst J
Strahlenther Onkol; 2018 Apr; 194(4):318-324. PubMed ID: 29181556
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical Validation of PSMA Expression Measured by
Woythal N; Arsenic R; Kempkensteffen C; Miller K; Janssen JC; Huang K; Makowski MR; Brenner W; Prasad V
J Nucl Med; 2018 Feb; 59(2):238-243. PubMed ID: 28775203
[No Abstract] [Full Text] [Related]
12. Outcome prediction of SSTR-RADS-3A and SSTR-RADS-3B lesions in patients with neuroendocrine tumors based on
Gao J; Zhou J; Liu C; Pan Y; Lin X; Zhang Y
J Cancer Res Clin Oncol; 2024 May; 150(5):272. PubMed ID: 38795250
[TBL] [Abstract][Full Text] [Related]
13. Establishment and prospective validation of an SUV
Jiao J; Kang F; Zhang J; Quan Z; Wen W; Zhao X; Ma S; Wu P; Yang F; Guo W; Yang X; Yuan J; Shi Y; Wang J; Qin W
Theranostics; 2021; 11(17):8396-8411. PubMed ID: 34373749
[No Abstract] [Full Text] [Related]
14. Uptake of the prostate-specific membrane antigen-targeted PET radiotracer 18F-DCFPyL in elastofibroma dorsi.
Gorin MA; Marashdeh W; Ross AE; Allaf ME; Pienta KJ; Pomper MG; Rowe SP
Nucl Med Commun; 2017 Sep; 38(9):795-798. PubMed ID: 28704341
[TBL] [Abstract][Full Text] [Related]
15. Factors Predicting Metastatic Disease in
Chiu LW; Lawhn-Heath C; Behr SC; Juarez R; Perez PM; Lobach I; Bucknor MD; Hope TA; Flavell RR
J Nucl Med; 2020 Dec; 61(12):1779-1785. PubMed ID: 32303599
[TBL] [Abstract][Full Text] [Related]
16. [
Bauman G; Martin P; Thiessen JD; Taylor R; Moussa M; Gaed M; Rachinsky I; Kassam Z; Chin J; Pautler S; Lee TY; Valliant JF; Ward A
Eur Urol Focus; 2018 Sep; 4(5):702-706. PubMed ID: 28753797
[TBL] [Abstract][Full Text] [Related]
17. A Prospective Comparison of
Harmon SA; Bergvall E; Mena E; Shih JH; Adler S; McKinney Y; Mehralivand S; Citrin DE; Couvillon A; Madan RA; Gulley JL; Mease RC; Jacobs PM; Pomper MG; Turkbey B; Choyke PL; Lindenberg ML
J Nucl Med; 2018 Nov; 59(11):1665-1671. PubMed ID: 29602821
[TBL] [Abstract][Full Text] [Related]
18. Semiquantitative Parameters in PSMA-Targeted PET Imaging with [
Sahakyan K; Li X; Lodge MA; Werner RA; Bundschuh RA; Bundschuh L; Kulkarni HR; Schuchardt C; Baum RP; Pienta KJ; Pomper MG; Ross AE; Gorin MA; Rowe SP
Mol Imaging Biol; 2020 Feb; 22(1):181-189. PubMed ID: 31115751
[TBL] [Abstract][Full Text] [Related]
19. A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol.
Hofman MS; Murphy DG; Williams SG; Nzenza T; Herschtal A; Lourenco RA; Bailey DL; Budd R; Hicks RJ; Francis RJ; Lawrentschuk N
BJU Int; 2018 Nov; 122(5):783-793. PubMed ID: 29726071
[TBL] [Abstract][Full Text] [Related]
20. The role of (
Yilmaz U; Komek H; Can C; Altindag S
Ann Nucl Med; 2019 Aug; 33(8):545-553. PubMed ID: 31069696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
